Omnicef Omni-Pac Side Effects

Generic name: cefdinir

Note: This document contains side effect information about cefdinir. Some of the dosage forms listed on this page may not apply to the brand name Omnicef Omni-Pac.

Some side effects of Omnicef Omni-Pac may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.

For the Consumer

Applies to cefdinir: oral capsule, oral powder for reconstitution

Get emergency medical help if you have any of these signs of an allergic reaction while taking cefdinir (the active ingredient contained in Omnicef Omni-Pac) hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

• diarrhea that is watery or bloody;

• chest pain;

• fever, chills, body aches, flu symptoms;

• unusual bleeding;

• seizure (convulsions);

• pale or yellowed skin, dark colored urine, fever, confusion or weakness;

• jaundice (yellowing of the skin or eyes);

• fever, sore throat, and headache with a severe blistering, peeling, and red skin rash; or

• increased thirst, loss of appetite, swelling, weight gain, feeling short of breath, urinating less than usual or not at all.

Less serious side effects of cefdinir may include:

• nausea, stomach pain, indigestion, vomiting, mild diarrhea;

• headache, dizziness;

• diaper rash in an infant taking liquid cefdinir;

• mild itching or skin rash; or

• vaginal itching or discharge.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect.

For Healthcare Professionals

Applies to cefdinir: oral capsule, oral powder for reconstitution

Gastrointestinal

Reddish-colored stools have occurred when cefdinir (the active ingredient contained in Omnicef Omni-Pac) was taken with iron-containing products, and may be due to the formation of non-absorbable complexes in the GI tract.

Gastrointestinal side effects have included diarrhea (15%), nausea (3%), abdominal pain (1%), dyspepsia (0.7%), flatulence (0.7%), vomiting (0.7%), anorexia (0.3%), constipation (0.3%), dry mouth (03%), abnormal stools (0.3%), moniliasis (0.2%) and pseudomembranous colitis. Adverse effects reported during postmarketing experience with cefdinir, regardless of causality, have included stomatitis, acute enterocolitis, bloody diarrhea, hemorrhagic colitis, melena, upper GI bleed, peptic ulcer, and ileus.

Hypersensitivity

Hypersensitivity reactions associated with cephalosporin class antibiotics have included allergic reactions, anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, and toxic epidermal necrolysis. Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included anaphylaxis (with rare cases of fatality), serum sickness-like reactions, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

Dermatologic

Dermatologic side effects have included rash (0.9%) and pruritus (0.2%). Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included exfoliative dermatitis, erythema multiforme, and erythema nodosum.

Genitourinary

Genitourinary side effects have included vaginal moniliasis (4% of women), vaginitis (1% of women), leukorrhea (0.2% of women), increased urine leukocytes (2%), increased urine protein (1%), increased microhematuria (1%), increased urine glucose (0.9%), increased urine specific gravity (0.6%), decreased urine specific gravity (0.2%), increased urine pH (0.2%). Cephalosporins as a class have been associated with false-positive tests for urine glucose.

Nervous system

Nervous system side effects have included headache (2%), dizziness (0.3%), insomnia (0.2%), asthenia (0.2%), and somnolence (0.2%). Some cephalosporins have been associated with seizures in renally impaired patients. Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included loss of consciousness.

Hematologic

Hematologic side effects have included increased lymphocytes (1%), decreased lymphocytes (0.2%), increased white blood cells (0.9%), decreased white blood cells (0.7%), increased eosinophils (0.7%), decreased hemoglobin (0.3%), increased polymorphonuclear neutrophils (0.3%), decreased polymorphonuclear neutrophils (0.2%), and increased platelets (0.2%). Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included granulocytopenia, pancytopenia, leukopenia, thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, bleeding tendency, coagulation disorder, and disseminated intravascular coagulation. Cephalosporins as a class have been associated with aplastic anemia, hemolytic anemia, prolonged prothrombin time, hemorrhage, neutropenia, pancytopenia, and agranulocytosis.

Metabolic

Metabolic side effects have included increased gamma-glutamyltransferase (1%), increased alanine aminotransferase (0.7%), decreased bicarbonate (0.6%), increased phosphorus (0.6%), decreased phosphorus (0.3%), increased aspartate aminotransferase (0.4%), increased alkaline phosphatase (0.3%), increased blood urea nitrogen (0.3%), increased bilirubin (0.2%), increased lactate dehydrogenase (0.2%), and increased potassium (0.2%).

Hepatic

Hepatic side effects associated with cephalosporins as a class have included hepatic dysfunction, including cholestasis. Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice, and increased amylase.

Renal

Renal side effects associated with cephalosporins as a class have included renal dysfunction and toxic nephropathy. Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included acute renal failure and nephropathy.

Ocular

Ocular adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included conjunctivitis.

Respiratory

Respiratory adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included acute respiratory failure, asthmatic attack, drug-induced pneumonia, eosinophilic pneumonia, and idiopathic interstitial pneumonia.

Other

Adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included fever, shock, feeling of suffocation, and facial and laryngeal edema.

Cardiovascular

Cardiovascular adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included cardiac failure, chest pain, myocardial infarction, hypertension, and allergic vasculitis.

Musculoskeletal

Musculoskeletal adverse effects reported during postmarketing experience with cefdinir (the active ingredient contained in Omnicef Omni-Pac) regardless of causality, have included involuntary movements and rhabdomyolysis.

Other

Geriatric patients have been reported to experience a lower rate of adverse events, including diarrhea, than younger patients.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of information provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.